A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. Issue 12 (30th September 2021)

• Record Type: Journal Article
• Authors: van den Berg, Inge; Smid, Marcel; Coebergh van den Braak, Robert R. J.; van de Wiel, Mark A.; van Deurzen, Carolien H. M.; de Weerd, Vanja; Martens, John W. M.; IJzermans, Jan N. M.; Wilting, Saskia M.
• Is Part Of: Molecular oncology. Volume 15:Issue 12(2021)
• Page Start: 3348
• Page End: 3362
• Publication Date: 2021-09-30
• Subjects: colon cancer -- consensus molecular subtypes -- marker panel -- methylation; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1002/1878-0261.13098
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Consensus molecular subtypes (CMSs) can guide precision treatment of colorectal cancer (CRC). We aim to identify methylation markers to distinguish between CMS2 and CMS3 in patients with CRC, for which an easy test is currently lacking. To this aim, fresh‐frozen tumor tissue of 239 patients with stage I‐III CRC was analyzed. Methylation profiles were obtained using the Infinium HumanMethylation450 BeadChip. We performed adaptive group‐regularized logistic ridge regression with post hoc group‐weighted elastic net marker selection to build prediction models for classification of CMS2 and CMS3. The Cancer Genome Atlas (TCGA) data were used for validation. Group regularization of the probes was done based on their location either relative to a CpG island or relative to a gene present in the CMS classifier, resulting in two different prediction models and subsequently different marker panels. For both panels, even when using only five markers, accuracies were > 90% in our cohort and in the TCGA validation set. Our methylation marker panel accurately distinguishes between CMS2 and CMS3. This enables development of a targeted assay to provide a robust and clinically relevant classification tool for CRC patients. Abstract : Consensus molecular subtypes (CMSs) can guide precision treatment of colorectal cancer (CRC). However, an easy test to distinguish between CMS2 and CMS3 in patients with colorectal cancer is currently lacking. We developed two methylation marker panels distinguishing between CMS2 and CMS3, both with accuracies > 90% in our cohort and in TCGA validation set. This enables development of a targeted assay to provide a robust and clinically relevant classification tool for CRC patients.